Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.53 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 7/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31023151 | 1.00 | ALDH1A1 (0.56) | ALDH1A1HIF1AVCAM1KAT2BLMNA | |
| SCHEMBL12208065 | 0.85 | TDP1 (0.58) | ALDH1A1HIF1AVCAM1KAT2BLMNA | |
| SCHEMBL14880650 | 0.85 | ALDH1A1 (0.60) | ALDH1A1HIF1AVCAM1LMNARECQL | |
| SCHEMBL3120356 | 0.83 | ALDH1A1 (0.58) | ALDH1A1HIF1AVCAM1LMNARECQL | |
| SCHEMBL10959235 | 0.82 | TSHR (0.55) | ALDH1A1KAT2BLMNAKMT2AMEN1 | |
| SCHEMBL6356240 | 0.82 | SMN1; SMN2 (0.49) | ALDH1A1HIF1AVCAM1KAT2BLMNA | |
| SCHEMBL7615803 | 0.81 | ALDH1A1 (0.56) | ALDH1A1HIF1AVCAM1KAT2BLMNA | |
| SCHEMBL4124874 | 0.81 | ALDH1A1 (0.56) | ALDH1A1HIF1AVCAM1LMNARECQL | |
| SCHEMBL14899811 | 0.81 | ALDH1A1 (0.56) | ALDH1A1HIF1AVCAM1LMNARECQL | |
| SCHEMBL29990481 | 0.81 | ALDH1A1 (0.56) | ALDH1A1HIF1AVCAM1LMNARECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117659017-B | TRPML1/2 modulator compound, pharmaceutical composition, preparation method and application thereof | 北京华益健康药物研究中心 | 2026-05-15 | — | — | CN | disclosed |
| WO-2024130095-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-06-20 | — | — | WO | disclosed |
| CN-117659017-A | TRPML1/2 modulator compound, pharmaceutical composition, preparation method and application thereof | 北京华益健康药物研究中心 | 2024-03-08 | — | — | CN | disclosed |
| US-10035770-B2 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED (US) | 2018-07-31 | — | — | US | disclosed |
| US-20170267638-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2017-09-21 | — | — | US | disclosed |
| US-9643925-B2 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED | 2017-05-09 | — | — | US | disclosed |
| US-20160115133-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2016-04-28 | — | — | US | disclosed |
| US-9150564-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20150005296-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2015-01-01 | — | — | US | disclosed |
| US-8871769-B2 | Ureas and their use in the treatment of heart failure | CYTOKINETICS, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871768-B2 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20140038983-A1 | UREAS AND THEIR USE IN THE TREATMENT OF HEART FAILURE | CYTOKINETICS, INCORPORATED (US) | 2014-02-06 | — | — | US | disclosed |
| US-8513257-B2 | Ureas and their use in the treatment of heart failure | CYTOKINETICS, INCORPORATED (US) | 2013-08-20 | — | — | US | disclosed |
| US-20120172372-A1 | Ureas and Their Use in the Treatment of Heart Failure | CYTOKINETICS, INC. | 2012-07-05 | — | — | US | disclosed |
| US-20100216784-A1 | Compounds for Inhibiting Beta-Amyloid Production and Methods of Identifying the Compounds | MULLAN MICHAEL J | 2010-08-26 | — | — | US | disclosed |
| US-20080058330-A1 | Compounds and Combinations Thereof for Inhibiting Beta-Amyloid Production and Methods of Use Thereof | ROSKAMP RESEARCH LLC (US) | 2008-03-06 | — | — | US | disclosed |
| US-20070185130-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | ROSKAMP RESEARCH LLC | 2007-08-09 | — | — | US | disclosed |
| US-20070037855-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | ALZHEIMER'S INSTITUTE OF AMERICA, INC. | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058330-A1 | Compounds and Combinations Thereof for Inhibiting Beta-Amyloid Production and Methods of Use Thereof | APP, PSEN1, PSEN2 | ALDH1A1 3749/4885HIF1A 2476/4885VCAM1 513/4885 |
| US-20120172372-A1 | Ureas and Their Use in the Treatment of Heart Failure | TNNI3, TNNT2, MYLK2 | ALDH1A1 3361/4885HIF1A 1559/4885VCAM1 3066/4885 |
| US-20170267638-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TNNI3, TNNC1, TNNT2 | ALDH1A1 4381/4885HIF1A 2668/4885VCAM1 3142/4885 |
| US-20070185130-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | APP, PSEN1, PSEN2 | ALDH1A1 3939/4885HIF1A 2969/4885VCAM1 529/4885 |
| US-20070037855-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | APP, PSEN1, PSEN2 | ALDH1A1 3939/4885HIF1A 2969/4885VCAM1 529/4885 |
| US-20100216784-A1 | Compounds for Inhibiting Beta-Amyloid Production and Methods of Identifying the Compounds | APP, PSEN1, PSEN2 | ALDH1A1 3939/4885HIF1A 2969/4885VCAM1 529/4885 |
| US-20140038983-A1 | UREAS AND THEIR USE IN THE TREATMENT OF HEART FAILURE | TNNI3, TNNT2, MYLK2 | ALDH1A1 3361/4885HIF1A 1559/4885VCAM1 3066/4885 |
| US-20150005296-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TNNI3, TNNC1, TNNT2 | ALDH1A1 4381/4885HIF1A 2668/4885VCAM1 3142/4885 |
| US-20160115133-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TNNI3, TNNC1, TNNT2 | ALDH1A1 4381/4885HIF1A 2668/4885VCAM1 3142/4885 |
| US-10035770-B2 | Compounds, compositions and methods | TNNI3, TNNC1, TNNT2 | ALDH1A1 4381/4885HIF1A 2668/4885VCAM1 3142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.